Nicholas J. Sarlis
Hoofd Techniek/Wetenschap/O&O bij Sellas Life Sciences Group Ltd.
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Herve Hoppenot | M | 64 | 10 jaar | |
| Robert van Nostrand | M | 67 |
Sellas Life Sciences Group Ltd.
 Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | 7 jaar |
| John Varian | M | 64 |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | 7 jaar |
| Jane Wasman | F | 67 |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | 7 jaar |
| Stephen F. Ghiglieri | M | 63 |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | 7 jaar |
| Angelos Stergiou | M | 48 |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | 12 jaar |
| Dragan Cicic | M | 60 | 4 jaar | |
| Fabio Lopez | M | 49 |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | 7 jaar |
| Paul Clancy | M | 62 | 9 jaar | |
| Jean-Jacques Bienaimé | M | 70 | 9 jaar | |
| Louka T. Katseli | M | 72 |
National & Kapodistrian University of Athens
| 37 jaar |
| Peter Langmuir | M | - | 9 jaar | |
| Michael Morrissey | M | - | 8 jaar | |
| Vijay Iyengar | M | 51 | 8 jaar | |
| Catalina Loveman | F | - | 9 jaar | |
| Barry Flannelly | M | 66 | 10 jaar | |
| Farhad Ravandi-Kashani | M | - |
The University of Texas M.D. Anderson Cancer Center
 The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | 21 jaar |
| Steven Stein | M | 57 | 9 jaar | |
| John F. DeGroot | M | - |
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | 20 jaar |
| Yannis Stournaras | M | 67 |
National & Kapodistrian University of Athens
| 35 jaar |
| Georgios Mergos | M | 76 |
National & Kapodistrian University of Athens
| 38 jaar |
| David Scheinberg | M | 68 |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | 7 jaar |
| Titia de Lange | M | - |
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | 18 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Roy Whitfield | M | 70 | 23 jaar | |
| Gregory M. Torre | M | 71 | 1 jaar | |
| Aleksey N. Krylov | M | - | 1 jaar | |
| Patricia A. Schreck | F | 70 | 8 jaar | |
| Bryant Lim | M | 53 | 4 jaar | |
| Christopher Martin Nutting | M | - |
University of London
| 7 jaar |
| Kang Bor Lee | M | 70 |
University of London
| 6 jaar |
| Krishna Vaddi | M | 58 | 13 jaar | |
| Gene C. Mack | M | 50 | - | |
| Ting Mei Fu | M | 57 |
University of London
| 5 jaar |
| Hussam bin Saud Al-Saud | M | 64 |
University of London
| 4 jaar |
| Eric Siegel | M | 60 | - | |
| Ngai Man Ng | M | 62 |
University of London
| 4 jaar |
| Adam David Lindemann | M | 51 |
University of London
| 7 jaar |
| Edward Lam | M | - |
University of London
| 4 jaar |
| Antoine Souma | M | - |
University of London
| 5 jaar |
| Barbara Wood | F | 62 | 6 jaar | |
| Michael Charles A. Booth | M | 53 | 7 jaar | |
| Richard de Schutter | M | 83 | 12 jaar | |
| David Hastings | M | 62 | 11 jaar | |
| Richard Levy | M | 66 | 13 jaar | |
| Agiostratidou Gina | F | - |
University of London
| 4 jaar |
| Barry Michael Ariko | M | 78 | 14 jaar | |
| Karima Olokun-Ola | F | 54 |
University of London
| 4 jaar |
| Li-Ling Ch'ng | F | 53 |
University of London
| 3 jaar |
| Jeyakumar Palakrishnar | M | 55 |
University of London
| 3 jaar |
| Denis Macshane | M | 76 |
University of London
| 3 jaar |
| Stewart James Jackson | M | 59 |
University of London
| 1 jaar |
| Goik Kenzu | M | 52 |
University of London
| 3 jaar |
| Kin Ping Yim | M | 69 |
University of London
| 1 jaar |
| Chi Kwong Wong | M | 62 |
University of London
| 4 jaar |
| Hei Chun Chu | M | 59 |
University of London
| 3 jaar |
| Chee Yeong Lio | M | 54 |
University of London
| 3 jaar |
| Nadiah Wong binti Abdullah | F | 53 |
University of London
| 4 jaar |
| Lai Kiu Lam | M | - |
University of London
| 4 jaar |
| Atiff Gilli | M | 49 |
University of London
| 4 jaar |
| Hau Ling Tin | F | 62 |
University of London
| 4 jaar |
| Jason Downes | M | - |
University of London
| 3 jaar |
| Premshangar Venugopal | M | 53 |
University of London
| 4 jaar |
| Nazim Khan | M | - |
University of London
| 3 jaar |
| Randhir Singh | M | 61 |
University of London
| 3 jaar |
| Sharanjeet Kaur Gill | F | 53 |
University of London
| 4 jaar |
| Razif Ratha bin Abdullah | M | 68 |
University of London
| 3 jaar |
| Maurice Ernest Scully | M | 56 |
University of London
| 3 jaar |
| Paramalingam | M | - |
University of London
| 3 jaar |
| Ki Chi Yip | M | 58 |
University of London
| 3 jaar |
| Yeng Kwong Yuen | M | - |
University of London
| 4 jaar |
| Jian Zhang | M | 53 |
University of London
| 4 jaar |
| Sam Rahman | M | - |
University of London
| 3 jaar |
| Raheel Zia | M | 53 |
University of London
| 1 jaar |
| Cheuk Kwong Yeung | M | 62 |
University of London
| 4 jaar |
| Dion Walter Roseman | M | - |
University of London
| 1 jaar |
| Andrew Coyne | M | 58 |
University of London
| 4 jaar |
| Charlie Juxon Welsh | M | - |
University of London
| 4 jaar |
| Harren Jhoti | M | 61 |
University of London
| 3 jaar |
| Mark Anthony Vincent | M | - |
University of London
| 4 jaar |
| Andreas Rialas | M | 56 |
University of London
| 3 jaar |
| Kenneth Hughes | M | - |
University of London
| 3 jaar |
| Brian Sean Padgett | M | 57 |
University of London
| 4 jaar |
| Boon Hoe Ooi | M | 58 |
University of London
| 4 jaar |
| Robert Seeley | M | - |
University of London
| 4 jaar |
| Wai Tak Sung | M | 66 |
University of London
| 3 jaar |
| Sanjay Patel | M | - |
University of London
| 4 jaar |
| Ziad Bahaa-Eldin | M | - |
University of London
| 1 jaar |
| Sheila A. Lines | F | - |
University of London
| 3 jaar |
| Khalil Mahmoud Khalil Abul-Rubb | M | 48 |
University of London
| 3 jaar |
| Book Theng | M | 65 |
University of London
| 3 jaar |
| Pahamin Abdul Rajab | M | 78 |
University of London
| 3 jaar |
| Ping Shou Gan | M | 59 |
University of London
| 3 jaar |
| Wai Lin Lam | F | 55 |
University of London
| 4 jaar |
| Lin Chung Tse | M | 63 |
University of London
| 17 jaar |
| Chee Leong Wai | M | 66 |
University of London
| 3 jaar |
| John Savill | M | - |
University of London
| 3 jaar |
| Boon Siew Wong | F | 56 |
University of London
| 4 jaar |
| Kwok Chung Lee | M | 60 |
University of London
| 3 jaar |
| Richard Chilcott | M | - |
University of London
| 4 jaar |
| Sopheak Sok | M | 66 |
University of London
| 4 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigd Koninkrijk | 63 | 63.00% |
| Verenigde Staten | 32 | 32.00% |
| Bermuda | 7 | 7.00% |
| Griekenland | 3 | 3.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Nicholas J. Sarlis
- Persoonlijk netwerk
